Testosterone enanthate became the workhorse of testosterone replacement because it solved the frequency problem — and it was never regarded as pharmacokinetically good. A 1995 paper opens with the field's own verdict: preparations producing constant physiological testosterone serum levels are what long-term androgen-deficiency treatment requires, and all injectable testosterone esters used clinically for substitution of male hypogonadism are characterised by unfavourable pharmacokinetics.[1]
That is not a critic writing from outside. That is the andrology literature describing its own standard of care.
Why it won anyway
A longer fatty-acid chain than propionate means slower cleavage from the oil depot, which means a longer interval between injections. For a chronic, lifelong therapy that is a decisive practical advantage — enough to outweigh a concentration profile everyone acknowledged was imperfect.
It is a familiar pattern in medicine: the treatment that wins is often the one people will actually keep taking. The Endocrine Society guideline makes that consideration explicit, asking clinicians to weigh treatment burden alongside pharmacokinetics, patient preference, formulation-specific adverse effects and cost.[2]
What "unfavourable" means in numbers
The most usable human figures come from the dose-response study that administered weekly enanthate at five doses and reported the nadir concentration for each: 253, 306, 542, 1,345 and 2,370 ng/dL at 25, 50, 125, 300 and 600 mg respectively.[3]
Read those as the floor of each weekly cycle. The 25 mg group bottomed out at 253 ng/dL; the 600 mg group at 2,370 ng/dL — the latter far above any physiological target. There is no dose at which weekly enanthate produces a flat line; there is only a choice about where the floor and the ceiling sit.
The ceiling has been measured too. A 24-week randomised trial of 200 mg enanthate IM every two weeks against a nightly transdermal found the injection arm produced supraphysiological testosterone, bioavailable testosterone and estradiol for several days after each injection, with morning levels inside the normal range in only 19–84% of those men against 77–100% on the transdermal.[5]
The successor, and what it fixed
The long-acting undecanoate was developed against precisely this complaint — the 1995 title is literally that injectable testosterone undecanoate has more favourable pharmacokinetics and pharmacodynamics than enanthate.[1] One important caveat on that specific comparison: the experiment was run in long-term orchidectomised cynomolgus monkeys, not in men.[1]
The human data followed. Phase I studies of 1000 mg testosterone undecanoate in hypogonadal men found that, compared with published enanthate data, both TU preparations showed extended half-lives and serum levels not exceeding the upper limit of normal — with the castor-oil formulation reaching a half-life of 33.9 ± 4.9 days against 20.9 ± 6.0 for tea seed oil.[6]
That phrase — not exceeding the upper limit of normal — is the direct answer to enanthate's defining flaw. Clinical experience with the long-acting preparation then accumulated over the following decade.[4] It introduced its own formulation-specific issue, the oil-depot reaction covered in POME.
Longer intervals reduce injections. They do not remove the peak-and-trough shape; they stretch it.
What this means if you are on it
Enanthate at an appropriate dose can achieve the guideline's target of mid-normal testosterone concentrations.[2] "Unfavourable pharmacokinetics" is a statement about the shape of the curve across the interval, not a verdict that the treatment does not work.
Two practical consequences:
Timing your blood draw matters. A level means little without knowing where in the cycle it was taken. Ask your clinician when to draw relative to your last injection — covered in the 3-month panel.
Symptoms that track the cycle are worth reporting. They are a reason to discuss dose and interval, not a reason to self-adjust.
Frequently asked questions
Is enanthate outdated? It remains widely used and can reach the guideline's mid-normal target.[2] But the swing was engineered out: long-acting undecanoate holds serum levels within the normal range.[6] Worth knowing from the randomised comparison: biweekly enanthate produced abnormal hematocrit elevations in 43.8% of men versus 15.4% on a daily transdermal, though both maintained mood and sexual function.[5]
Why not inject more often to smooth it out? That is the dosing-interval argument, and it is a pharmacokinetic case rather than a proven outcome benefit — set out honestly in daily vs weekly dosing.
Is a higher dose better if I feel flat by day six? The dose-response data argue against reflexively raising it: higher concentrations raised hemoglobin and lowered HDL without improving mood or sexual function.[3]
Next in this series
Fifty years of a therapy men describe as working, then fading, then working again — and a first-year discontinuation pattern that follows.
Continue with the peak and crash problem.
References
6 sources
- Partsch CJ, Weinbauer GF, Fang R, et al. Injectable testosterone undecanoate has more favourable pharmacokinetics and pharmacodynamics than testosterone enanthate. Eur J Endocrinol. 1995;132(4):514–519. doi:10.1530/eje.0.1320514 · PMID 7711892
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. doi:10.1210/jc.2018-00229 · PMID 29562364
- Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281(6):E1172–E1181. doi:10.1152/ajpendo.2001.281.6.E1172 · PMID 11701431
- Saad F, Kamischke A, Yassin A, et al. More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate. Asian J Androl. 2007;9(3):291–297. doi:10.1111/j.1745-7262.2007.00275.x · PMID 17486268
- Dobs AS, Meikle AW, Arver S, et al. Pharmacokinetics, Efficacy, and Safety of a Permeation-Enhanced Testosterone Transdermal System in Comparison with Bi-Weekly Injections of Testosterone Enanthate for the Treatment of Hypogonadal Men. J Clin Endocrinol Metab. 1999;84(10):3469–3478. doi:10.1210/jcem.84.10.6078 · PMID 10522982
- Behre HM, Abshagen K, Oettel M, et al. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol. 1999;140(5):414–419. doi:10.1530/eje.0.1400414 · PMID 10229906
Practical questions about membership, labs and using the spray are answered in the Learn Hub FAQ.